Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Accumulated Expenses (2021 - 2025)

ARS Pharmaceuticals (SPRY) has disclosed Accumulated Expenses for 4 consecutive years, with $6.9 million as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses rose 270.89% to $6.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.9 million through Dec 2025, up 270.89% year-over-year, with the annual reading at $6.9 million for FY2025, 270.89% up from the prior year.
  • Accumulated Expenses hit $6.9 million in Q4 2025 for ARS Pharmaceuticals, up from $5.4 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $12.5 million in Q3 2021 to a low of $404000.0 in Q1 2022.
  • Historically, Accumulated Expenses has averaged $5.8 million across 4 years, with a median of $5.8 million in 2021.
  • Biggest five-year swings in Accumulated Expenses: crashed 93.82% in 2022 and later soared 270.89% in 2025.
  • Year by year, Accumulated Expenses stood at $6.5 million in 2021, then surged by 83.82% to $12.0 million in 2022, then tumbled by 84.54% to $1.9 million in 2024, then skyrocketed by 270.89% to $6.9 million in 2025.
  • Business Quant data shows Accumulated Expenses for SPRY at $6.9 million in Q4 2025, $5.4 million in Q3 2025, and $1.9 million in Q4 2024.